Clinical Design and Objectives

This Phase 1 study evaluates M3814 in combination with mitoxantrone, etoposide, and cytarabine in patients with relapsed or refractory acute myeloid leukemia (AML). The primary objective is to define the optimal dose and safety profile, with the first endpoint being the identification of dose‑limiting toxicities (DLTs) and the maximum tolerated dose (MTD). The patient cohort consists of high‑risk individuals who have not responded to prior therapy. The trial commenced in May 2020 and is currently in the enrollment‑completion phase.

Mechanism of Action of M3814

M3814 is an inhibitor of DNA‑dependent protein kinase (DNA‑PK), a key enzyme in DNA damage repair. By inhibiting DNA‑PK, it blocks proliferative signaling in cancer cells and may reduce resistance to radiation or chemotherapy, thereby potentially enhancing the efficacy of standard chemotherapeutic regimens. Because this mechanism operates via a pathway distinct from conventional cytotoxic agents, it is attracting interest as a novel therapeutic combination.

Current Treatment Landscape and Differentiation

Standard therapy for relapsed/refractory AML typically involves high‑dose chemotherapy or hematopoietic stem cell transplantation, yet response rates remain low and the risk of relapse is high. Combining M3814 with chemotherapy aims to overcome drug resistance through DNA‑repair inhibition, which could improve response rates compared with existing treatments. However, as a Phase 1 trial, safety validation remains a prerequisite.